ArticleTheranostics2024

Development of a CD39 nanobody and its enhancement to chimeric antigen receptor T cells efficacy against ovarian cancer in preclinical studies.

Yu-Chen Zhang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.